




PHARMACEUTICAL 2021

Sierra Oncology Inc.
Rank 151 of 402





PHARMACEUTICAL 2021

Sierra Oncology Inc.
Rank 151 of 402

The relative strengths and weaknesses of Sierra Oncology Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sierra Oncology Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 86% points. The greatest weakness of Sierra Oncology Inc. is the variable Net Income, reducing the Economic Capital Ratio by 68% points.

The company's Economic Capital Ratio, given in the ranking table, is 150%, being 102% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	106,470
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	9,353
Liabilities, Non-Current	175
Other Assets	965
Other Compr. Net Income	0
Other Expenses	142
Other Liabilities	0
Other Net Income	-15,819
Other Revenues	300
Property and Equipment	52
Research and Development	45,118
Selling, General and Administrative Expense	20,123

Output Variable	Value in 1000 USD
Assets	107,487
Liabilities	9,528
Expenses	65,383
Revenues	300
Stockholders Equity	97,959
Net Income	-80,902
Comprehensive Net Income	-80,902
Economic Capital Ratio	150%